Evaluation of $^{188}$Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model

Feng-Yun J Huang¹
Te-Wei Lee²
Chih-Hsien Chang³
Liang-Cheng Chen³
Wei-Hsin Hsu³
Chien-Wen Chang¹
Jem-Mau Lo¹

¹Department of Biomedical Engineering and Environmental Science, National Tsing Hua University, Hsinchu, Taiwan; ²Institute of Nuclear Energy Research, Longtan, Taiwan

Purpose: In this study, the $^{188}$Re-labeled PEGylated nanoliposome ($^{188}$Re-liposome) was prepared and evaluated as a therapeutic agent for glioma.

Materials and methods: The reporter cell line, F98, was prepared via Lentivirus expression kit system and used to set up the orthotopic glioma-bearing rat model for non-invasive bioluminescent imaging. The maximum tolerated dose applicable in Fischer344 rats was explored via body weight monitoring of the rats after single intravenous injection of $^{188}$Re-liposome with varying dosages before the treatment study. The OLINDA/EXM 1.1 software was utilized for estimating the radiation dosimetry. To assess the therapeutic efficacy, tumor-bearing rats were intravenously administered $^{188}$Re-liposome or normal saline followed by monitoring of the tumor growth and animal survival time. In addition, the histopathological examinations of tumors were conducted on the $^{188}$Re-liposome-treated rats.

Results: By using bioluminescent imaging, the well-established reporter cell line (F98) showed a high relationship between cell number and its bioluminescent intensity ($R^2=0.99$) in vitro; furthermore, it could also provide clear tumor imaging for monitoring tumor growth in vivo. The maximum tolerated dose of $^{188}$Re-liposome in Fischer344 rats was estimated to be 333 MBq. According to the dosimetry results, higher equivalent doses were observed in spleen and kidneys while very less were in normal brain, red marrow, and thyroid. For therapeutic efficacy study, the progression of tumor growth in terms of tumor volume and/or tumor weight was significantly slower for the $^{188}$Re-liposome-treated group than the control group ($P<0.05$). As a result, the lifespan of glioma-bearing rats treated with $^{188}$Re-liposome was prolonged 10.67% compared to the control group.

Conclusion: The radiotherapeutic evaluation by dosimetry and survival studies have demonstrated that passive targeting $^{188}$Re-liposome via systemic administration can significantly prolong the lifespan of orthotopic glioma-bearing rats while maintaining reasonable systemic radiation safety. Therefore, $^{188}$Re-liposome could be a potential therapeutic agent for glioblastoma multiforme treatment.

Keywords: $^{188}$Re, liposome, radionuclide therapy, bioluminescent imaging, glioma

Introduction
Glioma is the most common primary tumor in the central nervous system. Glioblastoma multiforme (GBM), a World Health Organization (WHO) grade IV malignant glioma, accounts for more than half of total primary gliomas, with an average survival time ranging from 12 to 15 months.¹ High morbidity and mortality make glioma the fourth most serious malignant cancer.² The current standard treatment for GBM is essential surgical resection followed by a combination of radiation therapy plus adjuvant chemotherapy with temozolomide.³,⁴ Despite tremendous efforts on the treatments of
GBM, prognoses remain poor, with an increase of only a few months in average survival time and the 5-year survival rate less than 10%.

Aside from surgery and chemotherapy, radiation therapy remains an important means of cancer treatment. Approximately 50% of all cancer patients are treated with radiation therapy with varying modalities including external beam, brachytherapy, and radionuclide therapy (RNT). In the past decade, RNT has been increasingly adopted as a therapeutic radiopharmaceutical for treatment of cancers. In particular, radiation via RNT can be deposited to the lesion at the cellular level whereas conventional external beam therapy is limited to a gross anatomical level.

A wide variety of nanoparticles have been developed as drug carriers for treatment of cancers. Early clinical trials of some drug-incorporated nanoparticles have shown their efficacious cancer treatments owing to the passive accumulation of nanoparticles in the tumors by enhanced permeability and retention (EPR) effect and reducing the drug side effects to the system. In recent years, radiolabeled nanoparticles such as $^{188}$Re-lipid nanoparticles and $^{188}$Re-liposome nanoparticles have been introduced for treatment of GBM via convection-enhanced delivery technique. These studies demonstrated that the survival of tumor-bearing rats was significantly prolonged with therapeutic radiopharmaceutical treatment. Although the convection-enhanced delivery technique affords apparent benefits for GBM treatment, it might still cause certain drawbacks in clinical practice.

Moreover, the complicated drug delivery technique may not be ready and convenient for routine clinical uses. Therefore, development of a convenient and effective strategy for drug delivery is demanding for conducting RNT on GBM.

Systemic administration of therapeutic radiopharmaceuticals is an alternative but more feasible option of drug delivery for clinical RNT. Most recently, a new drug under investigation, $^{188}$Re-labeled PEGylated nanoliposome ($^{188}$Re-liposome) has been successfully validated with a series of translational studies for treatment of colon cancer. Currently, it has also been approved by Department of Health, Taiwan for further human clinical trial for treatment of metastatic colon cancer (Phase I). According to our previous work, $^{188}$Re-liposome had been explored in orthotopic glioma-bearing rat model for diagnostic evaluation where systemic administration was employed for delivering the radiolabeled liposome nanoparticles.

In this study, we aimed to evaluate the therapeutic efficacy of $^{188}$Re-liposome for GBM in orthotopic glioma-bearing rat model where single intravenous injection of $^{188}$Re-liposome was employed. $^{188}$Re, a VII B family element in the periodic table, has a similar physicochemical property to $^{99m}$Tc. It exhibits a physical half-life of 16.9 hours. Specifically, it emits not only a diagnostic gamma ray ($E_{\gamma}=155$ KeV) but also a therapeutic beta radiation ($E_{\beta_{\max}}=2.1$ MeV). In order to prove our concept for treatment of GBM tumor by $^{188}$Re-liposome via single intravenous injection, the related serial experiments including establishment of luciferase expressing reporter cell (F98$\text{lac}^\text{+}$), maximum tolerated dose (MTD), bioluminescent imaging (BLI), radiation dosimetry (OLINDA/EXM), therapeutic efficacy, and so forth, were performed in this study.

Materials and methods

Materials

Lentivector expression kit system was obtained from System Biosciences (SBI) (Mountain View, CA, USA) and XenoLight $\beta$-Luciferin potassium salt was from PerkinElmer Inc. (Waltham, MA, USA). Distearoylphosphatidylcholine (DSPC), cholesterol and polyethylene glycol (MW ~2 kDa) – derived distearoylphosphatidylethanolamine (DSPE-PEG$_{2000}$) were purchased from Genzyme (Cambridge, MA, USA). Cell culture materials were purchased from GIBCO™ BRL (Grand Island, NY, USA). PD-10 column was purchased from GE Healthcare Bio-Sciences AB (Uppsala, Sweden). N,N-bis(2-mercaptopethyl)-N’,N’-diethylethylenediamine (BMEDA) was from ABX (Radeberg, Germany). Hematoxylin and eosin (H and E) staining agents were from Sigma-Aldrich Co. (St Louis, MO, USA). Zoletil® 50 anesthetic was from Virbac (Virbac Taiwan Co., Ltd., Taiwan). All other chemicals were from Merck (Darmstadt, Germany).

Cell culture and cell growth curve

The F98 glioma cell line was kindly provided by Dr Jong Hwang of National Yang Ming University, Taipei, Taiwan, which was originally produced by Dr Rolf F Barth of Ohio State University, Cincinnati, Ohio, USA. This cell line was transfected with the luciferase gene to express luciferase as reporter (F98$\text{lac}^\text{+}$) through Lentivector expression kit and the F98$\text{lac}^\text{+}$ cells were sorted via green fluorescent protein (GFP) by a fluorescence-activated cell sorter (BD FACSARia™ III, San Jose, CA, USA). The F98$\text{lac}^\text{+}$ cells were cultured in Dulbeco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 µM/mL streptomycin. Cells were incubated at 37°C in a humidified environment with 5% CO$_2$. 
For cell growth curve study, the F98\textsubscript{lu}c cells were seeded in a 12-well plate with 1×10\textsuperscript{6} cells in each well. The cells were harvested after incubation for 16, 24, 48, 72, 96, and 120 hours, respectively and the numbers of cells at each well were counted by a hemacytometer. The cell doubling time (\(T_d\)) was evaluated by the following formula:\textsuperscript{24}

\[
T_d = (T-T_0)\times\ln2/(\ln N_0-\ln N).
\]  

\textbf{Fischer344/F98\textsubscript{lu}c glioma model}

All animal studies were approved by the Institutional Animal Care and Use Committee at the Institute of Nuclear Energy Research, Taoyuan, Taiwan. The Fischer344/F98\textsubscript{lu}c orthotopic glioma bearing rat model was established according to the procedure as previous reported by Mathieu et al\textsuperscript{33} but with modification. The normal Fischer344 rats were supplied by the National Laboratory Animal Center, Taipei, Taiwan and were housed in a controlled environment with food and water provided ad libitum.

The rats (male, 12–13 weeks old) were anesthetized with isoflurane\textsuperscript{*} and then administered atropine sulfate (0.1 mg/kg) via subcutaneous injection; subsequently, the rats were deeply anesthetized by intraperitoneal injection of Zoletil\textsuperscript{®} and then administered atropine sulfate (0.1 mg/kg) via subcutaneous injection; subsequently, the rats were deeply anesthetized by intraperitoneal injection of Zoletil\textsuperscript{®} and Balanzine 2\% mixture at a 5:2 volume ratio (0.1 mL/100 g rat body weight). After anesthesia, the hair on the rat’s head was removed from the operative field. Then, the rats were immobilized by a stereotactic frame (Stoelting\textsuperscript{®}, Wood Dale, IL, USA). A 2 cm linear incision was carefully made and the immobilized for the following surgery. After removing the periosteum, a 1 mm diameter hole was created with a high-pressure extruder (LIPEX\textsuperscript{™}, Northern Lipids Inc., Burnaby, BC, Canada). Finally, normal saline was introduced via subcutaneous injection; subsequently, the rats were deeply anesthetized with 3\% isoflurane and then imaged continuously for 10 minutes with the IVIS\textsuperscript{™} system. To monitor Fischer344/F98\textsubscript{lu}c tumor growth curve in a relationship between bioluminescent intensity and time, the tumor bearing rats were imaged from Day 3 to Day 13 post-inoculation, respectively. After Day 13 imaging, the rats were sacrificed by CO\textsubscript{2} euthanasia and the brain tumor was dissected for histopathological examination (H and E staining). Tumoral luminescence intensity (photons/s) was quantified by conducting a region of interest assay using the Living Image software (Xenogen\textsuperscript{®}).

\textbf{Preparation of neutral PEGylated nanoliposomes}

The lipid film hydration–extrusion combining repeated freeze–thawing method was used to prepare neutral PEGylated nanoliposomes as previously reported.\textsuperscript{28} Briefly, the mixture of DSPC: cholesterol: DSPE-PEG\textsubscript{2000} at the molar ratio of 3:2:0.3 was dissolved in chloroform followed by removing the solvent with rotary evaporation. Then the 250 mM ammonium sulfate at pH 5.5 was used to rehydrate the dry lipid film at 60°C. After rehydration, the liposomes were extruded three times through polycarbonate membrane filters with varying pore sizes at 0.4, 0.2, 0.1, 0.05, and 0.03 \(\mu\)m, respectively (Sterlitech Corp., Kent, WA, USA) by a high-pressure extruder (LIPEX\textsuperscript{™}, Northern Lipids Inc., Burnaby, BC, Canada). Finally, normal saline was introduced to replace extraliposomal buffer via elution through a Sephadex G-50 column (Pharmacia, Uppsala, Sweden). The size and the zeta potential of the nanoliposomes were analyzed by a dynamic light scattering analyzer (N4 plus; Beckman Coulter Inc., CA, USA). Phospholipid concentration was measured via phosphorus assay with ultraviolet-visible spectrophotometry at \(\lambda=830\) nm (JascoV-530, Tokyo, Japan).\textsuperscript{29}

\textbf{Preparation of 188\textsuperscript{Re}-liposome}

188\textsuperscript{Re}-liposome was prepared as described previously.\textsuperscript{15,21,36} The carrier free 188\textsuperscript{Re}-perrhenate solution (Na\textsuperscript{188}ReO\textsubscript{4};
3.7–7.4 GBq) was produced from an in-house alumina-based
$^{188}$W/$^{188}$Re generator with the original $^{188}$W radionuclide purchased from Oak Ridge National Laboratory (Oak Ridge, TN, USA).

For $^{188}$Re-liposome preparation, the preformed PEGylated nanoliposomes and $^{188}$Re-BMEDA complex were added together into a vial at a volume ratio of 1:1 (1 mL:1 mL) and capped with rubber septum and aluminum foil. Then the solution mixture was incubated in a 60°C water bath shaking at 100 rpm for 30 minutes. After reaction, the preparation vial was taken out and cooled down at room temperature for 10 minutes. Subsequently, a PD-10 size exclusion column was utilized to purify $^{188}$Re-liposome from $^{188}$Re-BMEDA complex and free rhenium-188 (Na$^{188}$ReO$_4$) via elution with normal saline. Each 0.5 mL eluate was collected in an Eppendorf tube and the liposome opacity was visualized to monitor the position of $^{188}$Re-liposome. The radiochemical yield was calculated by the radioactivity of the collected product divided by the total initial loaded radioactivity for the separation.

**MTD of $^{188}$Re-liposome in Fischer344 rats**

The MTD of medication in animal trial was defined as the radioactivity dose below the dose resulting in either the death of any animal in groups of five animals or body weight loss of more than 20%. To obtain the MTD for referring therapeutic evaluation, the toxicity of $^{188}$Re-liposome in Fischer344 rats was estimated. First, fifteen normal male Fischer344 rats (12–13 weeks old) were randomly divided into three groups (five rats per group) and administered $^{188}$Re-Liposome (2.5 μmol phospholipids/0.5 mL) at dosage of 296, 333, and 370 MBq via single intravenous injection for respective groups. After medication, the body weight loss of rats of each group was recorded twice per week for 1 month and the lethality of radiation toxicity in rats was monitored every day for 1 month.

**Radiation dosimetry estimation**

Internal radiation-dose assessment of $^{188}$Re-liposome in nuclear medicine was simulated using OLINDA/EXM 1.1 computer software according to previous reports. In order to evaluate the equivalent dose (Sv) in humans, the relative organ-mass scaling method was used. Before starting computer calculation, the bio-distribution of $^{188}$Re-liposome in human (73 kg adult) organs was extrapolated from our previous results of percentage injected activity per gram for the organ (%IA/organ) in rats and then calculated according to the following formula:

$$\frac{(%IA/\text{organ})_{\text{human}}}{(%IA/\text{organ})_{\text{animal}}} \times \left(\frac{\text{kg}_{\text{IB weight}}}{\text{animal}}\right) \times \left(\frac{\text{organ}}{\text{kg}_{\text{IB weight}}}\right)_{\text{human}}$$

The extrapolated bio-distribution data (%IA/organ) of $^{188}$Re-liposome in human organs at 1, 4, 24, 48, and 72 hours was entered into OLINDA/EXM 1.1 software. The integral (MBq · s) information from selected 14 organs including heart contents (blood), muscle, testes, pancreas, stomach, small intestine, large intestine, kidney, spleen, liver, lung, heart, brain, and remainder of the body, was used to evaluate radiation dosimetry. The activity of remainder of the body was defined as the total activity in the body minus all of the activities from selected organs. In addition, the distribution of activity of remainder of the body was presumed to be uniform. To estimate tumoral absorbed dose (Gy) at different tumor sizes ranging from 0.01 to 6,000 g, the sphere model in OLINDA/EXM 1.1 software was used. The uptake value of tumor (%IA/g) in biodistribution study in rats was directly entered into OLINDA/EXM 1.1 software program for dosimetry estimation.

**Therapeutic efficacy evaluation**

To evaluate therapeutic efficacy of $^{188}$Re-Liposome in Fischer344/F98 orthotopic glioma bearing rat model, a total of 35 rats was used herein. For survival evaluation study, 14 tumor bearing rats were randomly divided into two groups (seven rats per group). Subsequently, the rats of two groups were administered normal saline (control group) and $^{188}$Re-liposome (333 MBq/0.5 mL; 2.5 μmol phospholipid/0.5 mL) via single intravenous injection on Day 7 post-inoculation, respectively. Then the rats were monitored for survival and body weight every day until death. In addition, a decrease in body weight of 20% or more compared with weight on the day of inoculation was considered as a humane endpoint for survival evaluation. For tumor-growth inhibition study, 21 tumor bearing rats were used. Nine rats per group were administered saline (control group) and $^{188}$Re-liposome (333 MBq/0.5 mL; 2.5 μmol phospholipid/0.5 mL) via single intravenous injection on Day 7 post-inoculation, respectively. Then, three rats from each group were randomly sacrificed with CO$_2$ euthanasia on Day 10, 14, and 17 post-inoculation, respectively (another 3 rats were sacrificed on Day 6 post-inoculation). The brain tumors were carefully dissected, measured, and weighed. The tumor volume (mm$^3$) was calculated according to the
formula, volume = 0.5 × length × width². Meanwhile, the histopathological examination of the tumors was performed on Day 14 post-inoculation by staining with H and E according to routine staining protocol.

Statistical analysis
All data were expressed as mean ± standard error of the mean (SEM). The unpaired Student’s t-test was used for group comparisons. For therapeutic efficacy evaluation studies, survival curves were compared by use of the logrank test (SPSS software; SPSS Inc., Chicago, IL, USA). Values of P<0.05 were considered significant.

Results
Bioluminescence of F98_luc cell line and in vitro growth curve
After sorting via GFP by FACS, the purity of luciferase-expressed F98_luc cells was greater than 95%. The luminescence emission of F98_luc cells was detected using BLI technique as shown in Figure 1A. The minimal amount of cells for effective detection using BLI device was approximately 195 cells per well. In addition, the intensity of bioluminescence was highly correlated with the total amount of F98_luc cells with the linear correlation coefficient between bioluminescent intensity and cell numbers fitted R²=0.99 (Figure 1C). The in vitro growth curve of F98_luc cells is shown in Figure 1B. The T_d of F98_luc cells was calculated to be 26.23 hours.

In vivo monitoring of Fischer344/F98_luc tumor growth
For monitoring brain tumor growth in vivo, the noninvasive images of tumor growth were acquired from Fischer344/F98_luc glioma-bearing rat model via BLI device at different time intervals (Figure 2A). The intensity of bioluminescence from tumor region was apparently enhanced as the time of post-inoculation increased. To understand the accurate trend of tumor growth curve, the quantitative region of interest analysis from bioluminescent images was carried out (Figure 2B). The tumor growth curve indicates that intensity of bioluminescence increased slowly and reached a plateau on Day 13 after inoculation.

Figure 1 Relationship between F98_luc cell number and bioluminescent intensity (n=3).
Notes: (A) In vitro monitoring of bioluminescence of F98_luc cells via BLI. (B) In vitro cell growth curve of F98_luc cells. (C) Linear correlation between mean cell number and mean bioluminescent intensity (R²=0.99).
Abbreviations: BLI, bioluminescent imaging; T_d, doubling time; h, hours.
Furthermore, the histopathological analysis of tumor parenchyma on Day 13 after inoculation shows that the phenomenon of central necrosis was observed in the tumor (Figure 2C).

Characterizations of PEGylated liposome and $^{188}$Re-liposome
The concentration of phospholipid in the prepared PEGylated liposome was $21.2\pm1.95\,\mu\text{mol/mL}$ ($n=3$). The hydrodynamic size of PEGylated liposome was $80.12\pm0.83\,\text{nm}$ ($n=3$) and the charge on the liposomal surface was $-2.02\pm0.96\,\text{mV}$ ($n=3$). High purity $^{188}$Re-BMEDA complex was prepared at high radiochemical yield ($>98\%$) and used to react with PEGylated liposome to form $^{188}$Re-liposome. No significant change of particle size was observed after the PEGylated liposome was further radio-labeled with $^{188}$Re. The radiochemical yield of $^{188}$Re-liposome was $88.75\%\pm1.46\%$ ($n=3$) and the radiochemical purity was greater than $95\%$.

MTD
Figure 3 shows 1 month body weight monitoring for MTD estimation with 296, 333, and 370 MBq of $^{188}$Re-liposome via single intravenous injection in normal Fischer344 rats, respectively. All treatment groups had body weight decrease (less than $20\%$ changes) at first and then the body weight gradually recovered to normal after Day 7 post-injection. However, one rat died after receiving 370 MBq treatment. Given the above experimental data, the MTD value for therapeutic evaluation with $^{188}$Re-liposome in the Fischer344 rats was estimated to be 333 MBq.
Radiation dosimetry

Table 1 shows the organ equivalent dose estimation of \(^{188}\)Re-liposome for humans via orthotopic glioma-bearing rat model. The high equivalent doses were found in the spleen (6.96 mSv/MBq) and the kidneys (1.2 mSv/MBq). Moderate equivalent doses were observed in the heart wall (0.89 mSv/MBq), liver (0.81 mSv/MBq), lung (0.43 mSv/MBq), small intestine (0.2 mSv/MBq), lower large intestine (0.14 mSv/MBq), pancreas (0.13 mSv/MBq), and stomach wall (0.12 mSv/MBq) etc. Slight equivalent doses were found in the normal brain (0.02 mSv/MBq), red marrow (0.05 mSv/MBq) and thyroid (0.07 mSv/MBq) and so forth. In addition, the tumoral absorbed doses were estimated to be 122 to 13.6 mGy/MBq corresponding to the tumor sizes of 1 to 10 g, respectively.

Therapeutic efficacy

Figure 4 shows the survival curves for \(^{188}\)Re-liposome and normal saline treatment on a Fischer344/F98\(_{re}\) glioma-bearing rat model. The result shows that the lifespan for the \(^{188}\)Re-liposome-treated group was significantly increased by 10.67% compared to control group \((P=0.007)\). The statistical analysis for therapeutic efficacy evaluation is summarized in Table 2. The maximum survival time for the \(^{188}\)Re-liposome-treated group and control group was 24 and 19 days, respectively. In addition, the median survival time was 20.75 and 18.75 days, respectively.

To monitor tumor growth inhibition, the treated rats were euthanized at predetermined times and the tumor masses were measured. The tumor size was found to decrease over time in the \(^{188}\)Re-liposome-treated group, indicating a potential therapeutic effect.

Table 1 shows the equivalent dose estimation of \(^{188}\)Re-liposome in human organs estimated from extrapolation of orthotopic glioma-bearing rat model.

<table>
<thead>
<tr>
<th>Organ</th>
<th>Estimated dose (mSv/MBq)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenals</td>
<td>7.62E-02</td>
</tr>
<tr>
<td>Brain</td>
<td>2.75E-02</td>
</tr>
<tr>
<td>Breasts</td>
<td>7.09E-02</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>7.64E-02</td>
</tr>
<tr>
<td>LL wall</td>
<td>1.35E-01</td>
</tr>
<tr>
<td>Small intestine</td>
<td>2.01E-01</td>
</tr>
<tr>
<td>Stomach wall</td>
<td>1.19E-01</td>
</tr>
<tr>
<td>UlI wall</td>
<td>7.29E-02</td>
</tr>
<tr>
<td>Heart wall</td>
<td>8.89E-01</td>
</tr>
<tr>
<td>Kidneys</td>
<td>1.20E+00</td>
</tr>
<tr>
<td>Liver</td>
<td>8.11E-01</td>
</tr>
<tr>
<td>Lungs</td>
<td>4.26E-01</td>
</tr>
<tr>
<td>Muscle</td>
<td>2.55E-02</td>
</tr>
<tr>
<td>Ovaries</td>
<td>7.16E-02</td>
</tr>
<tr>
<td>Pancreas</td>
<td>1.32E-01</td>
</tr>
<tr>
<td>Red marrow</td>
<td>5.13E-02</td>
</tr>
<tr>
<td>Osteogenic cells</td>
<td>1.14E-01</td>
</tr>
<tr>
<td>Skin</td>
<td>6.97E-02</td>
</tr>
<tr>
<td>Spleen</td>
<td>6.96E+00</td>
</tr>
<tr>
<td>Testes</td>
<td>5.41E-02</td>
</tr>
<tr>
<td>Thymus</td>
<td>7.27E-02</td>
</tr>
<tr>
<td>Thyroid</td>
<td>7.04E-02</td>
</tr>
<tr>
<td>Urinary bladder wall</td>
<td>7.09E-02</td>
</tr>
<tr>
<td>Uterus</td>
<td>7.16E-02</td>
</tr>
<tr>
<td>Total body</td>
<td>1.35E-01</td>
</tr>
<tr>
<td>Effective dose</td>
<td>3.34E-01</td>
</tr>
</tbody>
</table>

Note: The OLINDA/EXM 1.1 software was applied in the radiation dosimetry with equivalent doses estimated for a 73 kg male adult.

Abbreviations: LLI, lower large intestine; UlI, upper large intestine.

Figure 4 The Kaplan–Meier survival curves of Fischer344/F98\(_{re}\) orthotopic glioma bearing rat model n=7. Notes: Single intravenous injection of normal saline (•) or 333 MBq \(^{188}\)Re-liposome (¡) was performed on Day 7 post-inoculation as marked by an arrow.

Abbreviation: d, days.
were removed for further analysis. Figure 5 shows tumor growth inhibition after treating with $^{188}$Re-liposome and normal saline. All of the tumor masses removed from rats treated with $^{188}$Re-liposome were found to be significantly smaller than the tumor masses removed from control group (Figure 5A), consistent with the images observed in the pathomorphological examination (Figure 5B). In addition, the quantitative analysis from the removed tumors also showed that the tumor volume from the $^{188}$Re-liposome treated group declined significantly at Day 14 ($P=0.0291$) and Day 17 ($P=0.0177$) compared to control group (Figure 5C), as well as the tumoral mass weight at Day 10 ($P=0.0294$), Day 14 ($P=0.0489$), and Day 17 ($P=0.0007$) (Figure 5D).

**Discussion**

The bio-distribution, pharmacokinetics, and imaging of $^{188}$Re-liposome in the orthotopic glioma-bearing rat model have been studied in our recent report.21 Previous work revealed that $^{188}$Re-liposome is retained in the GBM tumor area with approximately 2 %ID/g with T/N (tumor-to-normal

<table>
<thead>
<tr>
<th>Injection</th>
<th>No of rat/group</th>
<th>Dose (MBq)</th>
<th>Maximum survival time (days)</th>
<th>Median survival time (days)</th>
<th>Prolongation in lifespan (%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{188}$Re-liposome</td>
<td>7</td>
<td>333</td>
<td>24</td>
<td>20.75</td>
<td>10.67</td>
<td>0.007</td>
</tr>
<tr>
<td>Normal saline</td>
<td>7</td>
<td>None</td>
<td>19</td>
<td>18.75</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

**Table 2** Therapeutic efficacy evaluation of 333 MBq $^{188}$Re-liposome in orthotopic glioma-bearing rat model

![Figure 5](image-url) **Figure 5** Tumor growth inhibition monitoring at Day 10, 14, and 17 after treatment with normal saline and $^{188}$Re-liposome, respectively (n=3).

**Notes:** (A) Photograph of excised tumor masses after treatment with normal saline (left) and $^{188}$Re-liposome (right). (B) Histological examination of H and E staining for tumor parenchyma at Day 14 post-treatment with normal saline (upper) and $^{188}$Re-liposome (bottom). (C) Tumor volume (mm$^3$) growth curve after treatment with normal saline (●) and $^{188}$Re-liposome (○). (D) Tumor weight (mg) growth curve after treatment with normal saline (●) and $^{188}$Re-liposome (○). * and *** indicating the significant differences with $P<0.05$ and $P<0.001$ between treated group and control group, respectively.

**Abbreviations:** d, days; H and E, hematoxylin and eosin.
brain) uptake ratio as high as 32.5 at 24 hours post-injection. To elucidate the mechanism underlying the significant accumulation of injected $^{188}\text{Re}$-liposome in a tumor, it is presumed that $^{188}\text{Re}$-liposome (~80 nm) can cross leaky blood–brain barrier (BBB) near the glioma followed by retention in the tumor parenchyma by EPR effect. Leaky BBB structure in the Fischer344/F98 rat has also been confirmed via immunohistochemistry assay of the brain.\textsuperscript{34} Moreover, as previously reported, the neutral, negatively-charged, and/or PEGylated liposome may display larger retention volume in the brain than positive charged/unshielded liposome.\textsuperscript{35} The critical exclusion size of the endothelial gap in human primary GBM (U87 MG cell line) was estimated to be 7–100 nm, which may allow the passage of the 80 nm sized $^{188}\text{Re}$-liposome nanoparticles.\textsuperscript{36} Based on the aforementioned substantial evaluation, $^{188}\text{Re}$-liposome is worthy of further development as a therapeutic agent in orthotopic glioma-bearing rat model via single intravenous injection as discussed in this study.

In order to determine the appropriate treatment dose of $^{188}\text{Re}$-liposome in glioma rat model, the MTD estimation of $^{188}\text{Re}$-liposome in normal Fischer344 rats was conducted before the therapeutic experiments. According to the related studies in the previous reports, the acute toxicity of $^{188}\text{Re}$-liposome in rats was estimated as the following.\textsuperscript{7,38} The rats administered 185 MBq $^{188}\text{Re}$-liposome only, via intravenous injection, showed slight body weight loss (without causing any death) until 1 month. In this study, three higher dosages (296, 333, and 370 MBq) of $^{188}\text{Re}$-liposome were tested separately for the MTD estimation experiment. The results showed none of the rats in each group lost body weight over 20% in the period of 1 month after injection except for one rat which died in the group with the highest dosage (370 MBq). From the above experiment, the MTD of $^{188}\text{Re}$-liposome for Fischer344 rats was estimated to be 333 MBq.

For BLI experiments, the F98 cells expressing luciferase were successfully constructed by lentiviral-mediated transfection. By suspending a serial number of F98\textsubscript{luc} cells in the 96-well plate, the in vitro BLI showed a good linear relationship ($R=0.99$) between the cell number and the photo intensity (Figure 1C); meanwhile, the minimum detectable bioluminescent signal was shown to locate at the cell number 195. These results are comparable to those reported in the literature.\textsuperscript{27} As shown in the BLI study, the GBM tumor images can be clearly displayed via F98\textsubscript{luc} reporter at different time points after inoculation; meanwhile, the tumor growth could be monitored by the intensity of bioluminescence. In vivo monitoring by BLI declared that the tumor growth in orthotopic Fischer344/F98\textsubscript{luc} model rose gradually until Day 13 post-inoculation and then plateaued (Figure 2B). The presentation of the plateau could reveal the phenomena as follows. First, the larger tumor size (>10 mm) could have shielded some extent of the bioluminescence. Second, the tumoral central core could have had areas of necrosis with hypoxia which would cause decreased expression of luciferase.\textsuperscript{39} The imaging information of in vivo BLI in Fischer344/F98\textsubscript{luc} model is in good compliance with a previous report in the literature.\textsuperscript{40} In short, the well-established Fischer344/F98\textsubscript{luc} model can provide convenient, rapid, and non-invasive monitoring of the orthotopic tumor growth.

The lifespan of the glioma-bearing rats treated with $^{188}\text{Re}$-liposome was found to have 10.67% prolongation compared to control group ($P<0.05$). In addition, the tumor volume or tumor weight monitoring after treatments displayed significant difference ($P<0.05$) between the $^{188}\text{Re}$-liposome-treated and control group. Although only ~2 %ID/g $^{188}\text{Re}$-liposome was retained in the tumor area,\textsuperscript{21} the dosage of 333 MBq was sufficient to damage the cancer cells, resulting in prolongation of the lifespan of the rats. Once $^{188}\text{Re}$-liposome was accumulated in the tumor area by EPR effect, the beta particle radiation emitted from $^{188}\text{Re}$ could powerfully damage the surrounding tumor cells, even spreading to the cells in the vicinity (>1 cm). This wide range of killing tumor capability by emitted β ray or electrons is known as “cross fire” effect,\textsuperscript{41} by destroying a tumor without necessarily targeting every cell within the tumor. Moreover, the cross fire effect may compensate for the insufficient extent for heterogeneous tumor uptake.\textsuperscript{42}

In combination with chemotherapy, $^{188}\text{Re}$-liposome could be further incorporated with doxorubicin or other drugs to multiply the therapeutic efficacy.\textsuperscript{43} Moreover, further modifications of liposome surface with lactoferrin may be beneficial for its trafficking across BBB, which may further improve the therapeutic efficacy.\textsuperscript{28} All of these novel designs would be added in our future work for developing the radio-labeled liposome system as a potential therapeutic agent for GBM for clinical use.

**Conclusion**

In this study, the MTD of $^{188}\text{Re}$-liposome on Fischer344 rats was estimated to be 333 MBq. Fischer344/F98\textsubscript{luc} glioma model could be efficiently used for tumor growth monitoring via non-invasive BLI. The in vivo evaluation of therapeutic efficacy by dosimetry estimation and survival studies have shown that passive targeting $^{188}\text{Re}$-liposome via systemic administration can contribute to significant prolonged lifespan of orthotopic glioma-bearing rats with reasonable
systemic radiation safety. Taken together, \(^{188}\text{Re}\)-liposome is worthy for further development as a potential diagnostic agent of RNT against GBM.

**Acknowledgments**

The authors would like to thank WL Wu for directing transfected work of F98 cell expressing luciferase as reporter (F98\(_{\text{lux}}\)) and Dr Tsai-Yueh Luo for providing the rhenium-188 from Division of Isotope Application, Institute of Nuclear Energy Research (INER). In addition, we also thank CY Yu, YJ Chang, WC Lee, CL Ho, WC Hsu, TJ Chang, CH Chuang, SJ Chen, and SP Chiu from Radiopharmacology Laboratory, Division of Isotope Application, INER, for the technical support and meaningful discussion. This study was financially supported by INER, Longtan, Taiwan and was partially supported by National Health Research Institute, Taiwan (NHRI-EX103-10221EC) and Ministry of Science and Technology, Taiwan (102-2113-M-007-006-MY2).

**Disclosure**

The authors declare no conflicts of interest in this work.

**References**


